| A Study of TEPEZZA® Treatment in Participants With Thyroid Eye Disease (NCT06389578) | Amgen | 2022-07-14 |
| A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) (NCT05276063) | Sling Therapeutics, Inc. | 2022-07-01 |
| A Study to Evaluate the Safety, Preliminary Efficacy, and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or Thyroid Eye Disease (NCT05331300) | Lassen Therapeutics 1 PTY LTD | 2022-06-06 |
| Development of an AI Solution to Evaluate Clinical Activity of TAO Using Periocular Images Taken by Smartphones in Patients With Thyroid Dysfunction (NCT05731154) | Seoul National University Bundang Hospital | 2021-12-22 |
| Local Betamethasone Versus Triamcinolone Injection in Management of Thyroid Eye Disease (NCT04976816) | Assiut University | 2021-12-01 |
| A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED) (NCT04737330) | Novartis Pharmaceuticals | 2021-11-29 |
| TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study (NCT05002998) | Amgen | 2021-09-16 |
| A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease (NCT04583735) | Amgen | 2021-09-02 |
| Tocilizumab in Corticosteroid-Resistant Graves' Orbitopathy (Thyroid Eye Disease) (NCT06367517) | Medical University of Warsaw | 2021-05-20 |
| The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction (NCT06275373) | Walter Reed National Military Medical Center | 2021-05-12 |
| AS-OCT of the Cornea in Thyroid Diseases (NCT05241626) | Minia University | 2021-05-11 |
| Customized Multiple Orbital Wall Decompression for Sight-threatening Graves's Ophthalmopathy (NCT05627401) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2021-01-01 |
| Anti-VEGF Therapy for Acute Thyroid Eye Disease (NCT04311606) | Massachusetts Eye and Ear Infirmary | 2020-11-02 |
| Tamsulosin for Thyroid Lid Retraction (NCT04359979) | Sheba Medical Center | 2020-05-01 |
| The Effect of a New Antioxidant Combination (ASTED) on Mild Thyroid Eye Disease (TED) (NCT02393183) | Iran University of Medical Sciences | 2019-07-15 |
| Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study (NCT03461211) | Amgen | 2018-04-16 |
| Corneal Tomographic Parameters in TGD (NCT04433936) | Ameera Gamal Abdelhameed | 2018-02-01 |
| Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study (NCT03298867) | Amgen | 2017-10-04 |
| Celecoxib for Thyroid Eye Disease (NCT02845336) | Johns Hopkins University | 2017-03-05 |
| The Therapeutic Effect of Dysthyroid Optic Neuropathy (NCT04096612) | Sun Yat-sen University | 2016-01-01 |
| B-cell Depletion Therapy With Rituximab for Thyroid Eye Disease (NCT02316691) | University of Pittsburgh | 2016-01-01 |
| The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients. (NCT01927406) | Stanford University | 2014-06-01 |
| Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease (NCT01738243) | University of California, Los Angeles | 2013-12-01 |
| Twenty-four Hour Intraocular Pressure Patterns in Patients With Uncontrolled Thyroid Eye Disease (NCT01798966) | Sensimed AG | 2013-02-01 |
| Tocilizumab Treatment in Graves´ Ophthalmopathy (Graves´ Orbitopathy or Thyroid Eye Disease) (NCT01297699) | Hospital Clinico Universitario de Santiago | 2012-03-01 |
| Disappearance of Graves' Orbitopathy (NCT03103607) | University of Pisa | 2010-01-01 |
| Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye Disease (NCT04040894) | Amgen | |